Company Overview - Angel Yeast Co., Ltd. is located at 168 Chengdong Avenue, Yichang City, Hubei Province, established on March 25, 1998, and listed on August 18, 2000. The company primarily engages in the development, production, and operation of yeast, yeast derivatives, and related biological products [1] - The main business revenue composition includes yeast and related industries at 90.62%, other at 7.89%, and packaging materials at 4.07% [1] Financial Performance - For the first half of 2025, Angel Yeast achieved operating revenue of 7.899 billion yuan, a year-on-year increase of 10.10%, and a net profit attributable to shareholders of 799 million yuan, a year-on-year increase of 15.66% [2] - Since its A-share listing, Angel Yeast has distributed a total of 3.961 billion yuan in dividends, with 1.341 billion yuan distributed in the last three years [3] Stock Market Activity - As of September 29, Angel Yeast's stock price was 39.70 yuan per share, with a market capitalization of 34.462 billion yuan. The stock has increased by 11.83% year-to-date [1] - The stock experienced a net outflow of 10.036 million yuan in principal funds, with significant selling pressure observed [1] - The company has appeared on the "Dragon and Tiger List" once this year, with the last occurrence on March 5, where it recorded a net buy of -136 million yuan [1] Shareholder Information - As of June 30, 2025, the number of shareholders was 63,900, a decrease of 5.74% from the previous period, with an average of 13,411 circulating shares per person, an increase of 6.42% [2] - Major shareholders include Hong Kong Central Clearing Limited as the second-largest shareholder with 36.9082 million shares, and Southern CSI 500 ETF as the fifth-largest shareholder with 9.0213 million shares [3]

Core Viewpoint - Aimeike's stock price has shown fluctuations with a recent increase of 2.01%, while the company faces a decline in revenue and profit for the first half of 2025 compared to the previous year [1][2]. Financial Performance - As of September 19, 2025, Aimeike reported a revenue of 1.299 billion yuan, a year-on-year decrease of 21.59%, and a net profit attributable to shareholders of 789 million yuan, down 29.57% year-on-year [2]. - The company has distributed a total of 3.887 billion yuan in dividends since its A-share listing, with 3.012 billion yuan distributed over the past three years [3]. Stock Market Activity - On September 26, Aimeike's stock was priced at 183.47 yuan per share, with a market capitalization of 55.517 billion yuan and a trading volume of 393 million yuan [1]. - The stock has increased by 3.35% year-to-date, but has seen a decline of 1.12% over the last five trading days and 4.83% over the last twenty days [1]. Shareholder Information - As of September 19, 2025, Aimeike had 56,400 shareholders, an increase of 3.28% from the previous period, with an average of 3,700 circulating shares per shareholder, a decrease of 3.17% [2]. - The top ten circulating shareholders include Hong Kong Central Clearing Limited and various ETFs, with some shareholders increasing or decreasing their holdings [3].

Group 1 - The stock price of Liangmianzhen increased by 2.04% on September 24, reaching 6.01 CNY per share, with a total market capitalization of 3.305 billion CNY [1] - The company has seen a year-to-date stock price increase of 18.77%, with a recent decline of 3.84% over the last five trading days [1] - Liangmianzhen has appeared on the trading leaderboard four times this year, with the most recent instance on April 18, where it recorded a net buy of -8.0748 million CNY [1] Group 2 - As of June 30, the number of shareholders for Liangmianzhen increased by 27.15% to 51,100, while the average circulating shares per person decreased by 21.35% to 10,761 shares [2] - For the first half of 2025, Liangmianzhen reported a revenue of 522 million CNY, reflecting a year-on-year growth of 1.02%, but a net profit loss of 5.0842 million CNY, down 46.62% year-on-year [2] Group 3 - Since its A-share listing, Liangmianzhen has distributed a total of 202 million CNY in dividends, with 33 million CNY distributed over the past three years [3]

Core Viewpoint - Mingchen Health's stock price has experienced a decline of 9.88% year-to-date, with significant drops in recent trading periods, indicating potential challenges in the market [2]. Company Overview - Mingchen Health Products Co., Ltd. is located in the Lian Nan Industrial Zone, Chenghai District, Shantou City, Guangdong Province, and was established on December 14, 1994, with its listing date on December 18, 2017 [2]. - The company specializes in the research, development, production, and sales of health care products, including shampoos, conditioners, shower gels, gel water, and skincare products [2]. - The revenue composition of the company is as follows: 76.84% from online games, 23.09% from daily chemical products, and 0.07% from other sources [2]. Financial Performance - For the first half of 2025, Mingchen Health achieved operating revenue of 712 million yuan, representing a year-on-year growth of 7.07%. However, the net profit attributable to shareholders decreased by 31.97% to 41.06 million yuan [2]. - The company has distributed a total of 151 million yuan in dividends since its A-share listing, with 46.57 million yuan distributed over the past three years [3]. Shareholder Information - As of June 30, 2025, the number of shareholders for Mingchen Health was 18,800, an increase of 2.88% from the previous period, with an average of 14,063 circulating shares per person, a decrease of 2.80% [2]. - Notable institutional holdings include Huaxia Industry Prosperity Mixed Fund, which is the fourth-largest shareholder with 5.2765 million shares, an increase of 1.6392 million shares from the previous period [3].

Core Viewpoint - The stock of Proya Cosmetics has experienced a decline in recent trading sessions, with a notable drop in both price and trading volume, indicating potential concerns among investors [1][2]. Financial Performance - For the first half of 2025, Proya achieved a revenue of 5.362 billion yuan, representing a year-on-year growth of 7.21% [2]. - The net profit attributable to shareholders for the same period was 799 million yuan, reflecting a year-on-year increase of 13.80% [2]. Stock Market Activity - As of September 23, Proya's stock price was 78.69 yuan per share, with a market capitalization of 31.162 billion yuan [1]. - The stock has seen a year-to-date decline of 5.78%, with a 14.46% drop over the past 20 trading days [1]. Shareholder Information - As of June 30, 2025, the number of shareholders increased to 60,300, up by 18.25% from the previous period [2]. - The average number of circulating shares per shareholder decreased by 15.43% to 6,560 shares [2]. Dividend Distribution - Proya has distributed a total of 1.81 billion yuan in dividends since its A-share listing, with 1.225 billion yuan distributed over the past three years [3]. Institutional Holdings - As of June 30, 2025, the top ten circulating shareholders included Hong Kong Central Clearing Limited, which reduced its holdings by 12.39 million shares [3]. - Southern CSI 500 ETF increased its holdings by 504,700 shares, while other institutional investors showed varied changes in their shareholdings [3].

Core Viewpoint - Fangsheng Pharmaceutical's stock price has shown fluctuations, with a year-to-date increase of 12.39% and a recent decline over the past 20 days, indicating mixed market sentiment [2]. Company Overview - Fangsheng Pharmaceutical, established on October 13, 1997, and listed on December 5, 2014, is located in Changsha, Hunan Province. The company specializes in the research, production, and sales of traditional Chinese medicine for cardiovascular, orthopedic, pediatric, and anti-infection treatments [2]. - The company's revenue composition is primarily from product sales (94.62%) and service provision (5.38%) [2]. - As of June 30, 2025, the company had 33,100 shareholders, a slight increase of 0.37% from the previous period, with an average of 13,245 circulating shares per shareholder, down by 0.36% [2]. Financial Performance - For the first half of 2025, Fangsheng Pharmaceutical reported a revenue of 834 million yuan, a year-on-year decrease of 8.35%. However, the net profit attributable to shareholders increased by 23.67% to 169 million yuan [2]. - The company has distributed a total of 689 million yuan in dividends since its A-share listing, with 484 million yuan distributed over the past three years [3]. Shareholder Structure - As of June 30, 2025, the top three circulating shareholders include ICBC Medical Health Stock (000831) with 5.40 million shares, unchanged from the previous period, and Rongtong Health Industry Flexible Allocation Mixed A/B (000727) with 5.00 million shares, which increased by 500,000 shares [3]. - Notably, E Fund Healthcare Industry Mixed A (110023) and Anxin Pharmaceutical Health Stock A (010709) have exited the top ten circulating shareholders list [3].

Company Overview - Yuyuan Group Co., Ltd. is located at 2 Fuxing East Road, Huangpu District, Shanghai, established on November 25, 1987, and listed on September 2, 1992 [2] - The company's main business includes gold and jewelry sales, catering and pharmaceutical business, and real estate development [2] - Revenue composition: 76.09% from industrial operations, 17.20% from property development and sales, and 6.71% from commercial comprehensive operations and property services [2] Stock Performance - Yuyuan's stock price has decreased by 6.10% year-to-date, with a 4.25% drop over the last five trading days and a 5.02% decline over the last 20 days, while it increased by 6.35% over the last 60 days [2] - As of September 23, the stock price was 5.86 CNY per share, with a market capitalization of 22.836 billion CNY [1] Financial Performance - For the first half of 2025, Yuyuan reported revenue of 19.112 billion CNY, a year-on-year decrease of 30.68%, and a net profit attributable to shareholders of 62.814 million CNY, down 94.50% year-on-year [2] - The company has distributed a total of 10.042 billion CNY in dividends since its A-share listing, with 2.832 billion CNY distributed over the past three years [3] Shareholder Information - As of June 30, the number of shareholders was 83,300, a decrease of 2.66% from the previous period, with an average of 46,702 circulating shares per shareholder, an increase of 2.73% [2] Market Activity - On September 23, the net outflow of main funds was 6.8864 million CNY, with significant selling activity amounting to 7.2643 million CNY, representing 42.15% of total transactions [1]

Core Viewpoint - Aimeike's stock price has shown volatility, with a recent decline of 2.00% and a total market capitalization of 55.374 billion yuan, reflecting a mixed performance in the market [1] Financial Performance - For the first half of 2025, Aimeike reported a revenue of 1.299 billion yuan, a year-on-year decrease of 21.59%, and a net profit attributable to shareholders of 789 million yuan, down 29.57% year-on-year [2] - Cumulative cash dividends since Aimeike's A-share listing amount to 3.887 billion yuan, with 3.012 billion yuan distributed over the past three years [3] Shareholder Information - As of September 10, 2025, Aimeike had 54,600 shareholders, a decrease of 0.91% from the previous period, with an average of 3,822 circulating shares per shareholder, an increase of 0.92% [2] - The top ten circulating shareholders include Hong Kong Central Clearing Limited, holding 6.9808 million shares (a decrease of 1.0906 million shares), and Huabao CSI Medical ETF, holding 5.0610 million shares (an increase of 0.0607 million shares) [3] Stock Performance - Aimeike's stock has increased by 2.40% year-to-date, but has seen a decline of 5.70% over the last five trading days and 5.19% over the last twenty days [1] - The stock's trading volume on September 22 was 188 million yuan, with a turnover rate of 0.49% [1] Business Overview - Aimeike, established on June 9, 2004, specializes in the research, production, and sales of biomedical soft tissue repair materials, with its main revenue sources being solution injection products (57.27%) and gel injection products (37.97%) [1] - The company operates within the beauty care and medical aesthetics industry, focusing on medical consumables [1]

Core Viewpoint - Huaxi Bio's stock price has shown fluctuations, with a year-to-date increase of 8.82% but a recent decline of 7.48% over the past five trading days, indicating potential volatility in investor sentiment [2]. Company Overview - Huaxi Bio, established on January 3, 2000, and listed on November 6, 2019, is located in Jinan, Shandong Province. The company specializes in microbial fermentation and cross-linking technologies, developing bioactive materials that contribute to human health [2]. - The company has a comprehensive business model that spans from raw materials to medical terminal products, functional skincare products, and functional foods, serving global pharmaceutical, cosmetic, food manufacturing companies, medical institutions, and end-users [2]. Revenue Composition - The revenue composition of Huaxi Bio is as follows: 40.34% from skin science innovation transformation, 29.76% from medical terminal products, 27.70% from raw materials, and 2.17% from other sources [2]. Financial Performance - For the first half of 2025, Huaxi Bio reported a revenue of 2.261 billion yuan, a year-on-year decrease of 19.57%, and a net profit attributable to shareholders of 221 million yuan, down 35.38% year-on-year [2]. Shareholder Information - As of June 30, 2025, Huaxi Bio had 32,500 shareholders, an increase of 1.78% from the previous period. The average circulating shares per person decreased by 1.75% to 14,799 shares [2]. - The company has distributed a total of 1.138 billion yuan in dividends since its A-share listing, with 528 million yuan distributed over the past three years [3]. Institutional Holdings - The top ten circulating shareholders include notable ETFs, with Huaxia SSE Sci-Tech Innovation Board 50 ETF holding 10.6429 million shares, a decrease of 244,800 shares from the previous period. Other ETFs have shown varying changes in their holdings [3].

Core Viewpoint - Renhe Pharmaceutical's stock price has shown fluctuations, with a recent decline of 2.00% on September 19, 2023, and a total market capitalization of 8.918 billion yuan [1] Group 1: Stock Performance - Year-to-date, Renhe Pharmaceutical's stock price has increased by 13.55%, but it has seen a decline of 0.62% over the last five trading days and 4.21% over the last twenty days [2] - The stock has experienced a 17.53% increase over the last sixty days [2] Group 2: Financial Performance - For the first half of 2025, Renhe Pharmaceutical reported a revenue of 1.975 billion yuan, a year-on-year decrease of 16.46%, and a net profit attributable to shareholders of 290 million yuan, down 13.87% year-on-year [2] - Cumulative cash dividends since the company's A-share listing amount to 1.962 billion yuan, with 770 million yuan distributed over the last three years [3] Group 3: Shareholder Information - As of June 30, 2025, the number of shareholders for Renhe Pharmaceutical was 104,400, a decrease of 2.76% from the previous period [2] - The top ten circulating shareholders include Hong Kong Central Clearing Limited and Southern CSI 1000 ETF, with both increasing their holdings compared to the previous period [3]